Spike protein in the skin after COVID-19 vaccination

 A 64-year-old man with active rheumatoid arthritis (RA) developed painful skin eruptions in both legs and hands 13 days after the first dose of mRNA COVID-19 vaccination, BNT162b2. The lesions were exacerbated after the second dose of BNT162b2 vaccination, although he did not have a fever or any systemic symptoms. Laboratory examination revealed no remarkable change in blood counts, liver, or renal function except for mild increase of d-dimer suggesting abnormal coagulation. 

Biopsy from the necrotic nodule in the left popliteal fossa revealed necrotic epidermis and underlying occlusive vasculopathy in the middle to deep dermis with inflammatory infiltrates with neutrophils, leukocytoclasia, fibrin exudation, extravasated erythrocytes, and microthrombi (see panels B and C in the Figure). Also, there were lymphocytic infiltrates into the subcutaneous fat tissue (panel D). Histological diagnosis of necrotizing vasculitis was made. In 88 day of the disease onset, some of the vesicopapular lesions turned to be necrotic nodule be necrotic nodules and groups of vesicles on red macules newly developed in the both legs. Varicella Zoster Virus (VZV) was suspected. Immunostaining with anti-VZV was positive for the degenerated keratinocytes in the vesicle, making a final diagnosis of VZV infection. It was also confirmed with PCR using extracted DNA from two biopsied specimens taken at the early and late stages of 2-month intervals, that is, necrotic nodules and vesicles, respectively. Immunostaining with anti-coronavirus spike protein (SP) antibody revealed the SP expression in the intravesicular cells in the epidermis and endothelial cells of the inflamed vessels in the dermis. The SP was also found in the endothelial cells of venules in the subcutaneous fat tissue underlying the herpetic vasculitis lesion.


REFERENCE
Yamamoto M, Kase M, Sano H, Kamijima R, Sano S. Persistent varicella zoster virus infection following mRNA COVID‐19 vaccination was associated with the presence of encoded spike protein in the lesion. Journal of Cutaneous Immunology and Allergy.
 

Comments

Post a Comment

Popular posts from this blog

A New Onset of Ulcerative Colitis post-2nd-breakthrough-COVID-19

Image
A 21-year-old non-smoking Caucasian male with a history of acute pancreatitis but no other medical issues or family history had two doses of the BNT162b2 mRNA COVID-19 vaccine.  Four months after the second dose he had his first episode of COVID-19. Although not hypoxic, he felt pretty unwell for a week, with a severe cough, fever, generalized body ache, headache, and loss of taste. He received the third dose of the vaccine two months after recovering from COVID. Nine months after the third dose, he had the second episode of COVID-19, during which he was mildly unwell for three days, recovered, and did not require any anti-viral medication or antibiotics. One week post the second episode of COVID-19, he developed diarrhea and abdominal pain. It then progressed to bloody diarrhea. Ulcerative colitis was diagnosed based on his clinical symptoms, biopsy changes, and the exclusion of other causes.  There are ten published case reports about the newly diagnosed ulcerative colitis associate
Read more

Navigating the Tripledemic: JN.1, RSV, and Flu Update

Image
The respiratory viruses are out there.  Wastewater viral activity levels for COVID-19 , as reported by the Centers for Disease Control and Prevention, have reached the highest point since the Omicron surge in 2022. The levels are also high in Canada . The three primary respiratory illnesses continue to circulate at very high levels. But despite the triple threat of  SARS-Cov-2, respiratory syncytial virus ( RSV ) and the flu , there is a notable lack of community attention.   JN.1 (Pirola,  BA.2.86 ,  with additional L455S mutation, descending from a  de-escalated  variant of concern BA.2), initially detected on August 25 2023, has evolved from a variant under monitoring to a  variant of interest. Variants like Acrux (XBB.2.3, that began to spread worldwide soon after WHO declared the end of the pandemic) are  no longer relevant , but a few now less prevalent variants such as  Centaurus  (BA.2.75) and XBB, a hybrid of Centaurus with BA.2 lineage, that  gave rise to  Eris , its descend
Read more

Chronic SARS-CoV-2 Shedding

Image
Chronic viral shedding, a condition where the virus continues to be released from an individual's body long after the initial infection, has been observed in many infectious diseases, including COVID-19.  In such cases, individuals may remain asymptomatic or experience only mild symptoms while the virus persists. It remains detectable in repeated tests over an extended period and can still infect others even in nasal swab is negative. This was evident in our study.    Recent research by Conway et al. (2024) highlights the possibility of chronic SARS-CoV-2 infection, extending over several months and potentially years. Other studies have documented prolonged asymptomatic infections and extended viral shedding in moderate to severe beyond hospital discharge. Analysis of sequencing data on UK samples taken between 2 November 2020 and 15 August 2022 lead to estimates that 0.1–0.5% of infections may become persistent with typically rebounding high viral loads and last for at least 60 da
Read more